News

Regulators demand drug transparency

17-Mar-08

The DoH has promised to act after UK drug regulators called for tougher legislation on disclosure of adverse events by drug manufacturers.

The Medicines and Healthcare products Regulatory Agency (MHRA) wants the European Commission to tighten rules over providing drug safety information.

Companies should be legally obliged to disclose information on adverse effects even if noted outside of the European Union or when used outside of marketing authorisations, the MHRA says.

It also wants clear time scales for reporting information and sanctions for failing to comply.

Health minister Dawn Primarolo promised to strengthen the law 'to make it clear to all pharmaceutical companies that they should disclose any information that would have a bearing on the protection of health'.

The call follows a four-year investigation by the MHRA into handling of information on use of Seroxat (paroxetine) in under-18s by manufacturers GlaxoSmithKline (GSK).

The drug regulators say GSK should have disclosed data from some clinical trials earlier, although government prosecutors saw no realistic prospect of a conviction.

GSK has said it acted 'properly and responsibly'.

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Nursing Professional Issues

Lord Darzi's vision for nurses

What will Lord Darzi's NHS blueprint mean for practice and community nurses? Julie Griffiths investi... Read More

The NHS at 60 - Halting the rise of hospital-acquired infections

In the wake of the NHS's 60th birthday celebrations, Jenny Peters reflects on standards of cleanline... Read More

Singing to improve mental health

Singing workshops for mental health service users can promote social inclusion, writes Sarah Wild. Read More

Show all articles

Latest Clinical Articles

Clincal Review: Gout

Contributed by Dr Richard Stevens, consultant rheumatologist, Buckinghamshire Hospitals. Read more

Altitude-related illness

Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more

Clinical Review - Subfertility in women

Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more

Show all clinical articles

MIMS Product News

Relistor

New drug - Relistor

Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipat... Read more

Thalidomide available in the UK

Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK. Read more

MMR catch-up programme

The DoH has written to healthcare professionals to call for urgent action to help reduce the risk of... Read more

Jobs

 

Job of the Week